default author photo

Lingyun Ye

Dalhousie University

SCHOLARLY PAPERS

2

DOWNLOADS

235

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Downloads 171 (442,467)

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
Trina Racine, Glenn Hamonic, Elodie Pastural, Supriya Arora, Jocelyne Lew, Yun Cai, Erin Scruten, Rachelle Buchannan, May ElSherif, Lingyun Ye, Thomas Courant, Roland A. Ventura, Nicolas Collin, Matthieu Daugan, Luc Gagnon, Paul Hodgson, Sylvia van Drunen Little van den Hurk, Darryl Falzarano, Steve Sanche, Scott A. Halperin, Joanne Marie Langley and Volker Gerdts
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 120 (602,987)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 33 Posted: 08 Aug 2025
Glenn Hamonic, Elodie Pastural, Supriya Arora, Jocelyne Lew, Yun Cai, Erin Scruten, Rachelle Buchannan, May ElSherif, Lingyun Ye, Thomas Courant, Roland A. Ventura, Nicolas Collin, Matthieu Daugan, Luc Gagnon, Paul Hodgson, Sylvia van Drunen Little van den Hurk, Darryl Falzarano, Steve Sanche, Scott A. Halperin, Joanne Marie Langley, Volker Gerdts and Trina Racine
University of Saskatchewan - Vaccine and Infectious Disease Organization, affiliation not provided to SSRN, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 51 (1,072,374)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

2.

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double blinded phase 3 trial

Number of pages: 34 Posted: 01 Oct 2025
Adora Rooyakkers, Lingyun Ye, Pedro E. Cahn, Guillermo M. Ruiz-Palacios, Aamer Ikram, Fernando Lanas, Sergio Munoz, Omar Sued, Dmitry Lioznov, Vitalina Dzutseva, Ghazala Parveen, Tatyana Zubkova, Jing-Xin Li, Joanne Marie Langley, Ruijie Wang, Luis Barreto, Jin-Bo Gou, Tao Zhu, Carrie A. Whittle and Scott A. Halperin
affiliation not provided to SSRN, Dalhousie University, Fundación Huésped, affiliation not provided to SSRN, National Institutes of Health, Chak Shahzad, Universidad de la Frontera, Independent, affiliation not provided to SSRN, Ministry of Health of the Russian Federation, Novosibirsk State University, affiliation not provided to SSRN, Ministry of Health of the Russian Federation, Nanjing Medical University, Dalhousie University, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Dalhousie University and Dalhousie University
Downloads 64 (924,743)

Abstract:

Loading...

Efficacy, safety, immunogenicity, adenovirus type 5, vaccine, SARS-CoV-2, phase 3, booster